XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Capital Stock
3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Capital Stock

5. Capital Stock

 

Preferred Stock

 

The Company has authorized a total of 2,000,000 shares of preferred stock, par value $0.01 per share, none of which were outstanding at March 31, 2024 and December 31, 2023. The Company’s Board of Directors has the authority to issue preferred stock and to determine the rights, preferences, privileges, and restrictions, including voting rights.

 

Common Stock

 

On March 31, 2023, the Company entered into Securities Purchase Agreements, each a Purchase Agreement, with new and existing investors, the Investors, pursuant to which the Investors agreed to purchase in a private placement an aggregate of 510,134 shares of common stock for the aggregate purchase price of approximately $3.1 million with a purchase price per unit of $6.00, the Private Placement.

 

On January 18, 2023, Harvard Bioscience, Inc. converted 200 Series E Preferred Shares with accrued dividends of $9,545 into 31,933 shares of common stock.

 

Warrants

 

The Company had 1,113,622 warrants to purchase common stock outstanding as of March 31, 2024 with a weighted-average exercise price of $4.69.